Shoen C M, DeStefano M S, Cynamon M H
State University of New York Upstate Medical University, Syracuse, NY, USA.
Clin Infect Dis. 2000 Jun;30 Suppl 3:S288-90. doi: 10.1086/313876.
Rifalazil (formerly known as KRM-1648) in combination with isoniazid has been found to be more active than rifampin/isoniazid. Administration of rifalazil/isoniazid for 12 weeks resulted in continued apparent sterilization of organs 6 months after cessation of therapy. In this study we evaluated the durability of rifalazil/isoniazid treatment. Female CD-1 mice were infected with Mycobacterium tuberculosis ATCC 35801 (strain Erdman). Rifalazil and isoniazid were given in combination for 6 and 12 weeks; no mycobacteria could be cultured from spleens and lungs at both the 6-week and 12-week time points. After completing treatment, groups of mice treated with rifalazil/isoniazid for 6 or 12 weeks were observed without any additional treatment. These observation groups were compared to groups of rifalazil/isoniazid-treated mice (6 and 12 weeks) given dexamethasone for 7 and 8 weeks, respectively. Modest regrowth was noted in the spleens and lungs of the group treated with rifalazil/isoniazid for 6 weeks. Regrowth in the 6-weeks group was enhanced slightly by treatment with dexamethasone. In contrast, no regrowth was noted in the 12-weeks rifalazil/isoniazid group, and treatment with dexamethasone did not result in any regrowth.
利福拉齐（曾用名KRM - 1648）与异烟肼联合使用时，已被发现比利福平/异烟肼更具活性。给予利福拉齐/异烟肼治疗12周后，在治疗停止6个月后，各器官仍持续呈现明显的杀菌效果。在本研究中，我们评估了利福拉齐/异烟肼治疗的持久性。雌性CD - 1小鼠感染了结核分枝杆菌ATCC 35801（埃尔德曼菌株）。利福拉齐和异烟肼联合给药6周和12周；在6周和12周时间点，脾脏和肺部均未培养出分枝杆菌。完成治疗后，对用利福拉齐/异烟肼治疗6周或12周的小鼠组在不进行任何额外治疗的情况下进行观察。将这些观察组与分别给予地塞米松7周和8周的利福拉齐/异烟肼治疗小鼠组（6周和12周）进行比较。在用利福拉齐/异烟肼治疗6周的组的脾脏和肺部中观察到适度的再生长。地塞米松治疗使6周组的再生长略有增强。相比之下，在利福拉齐/异烟肼治疗12周的组中未观察到再生长，并且地塞米松治疗也未导致任何再生长。
